http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Matt Maddox Joins DirectDefense as Vice President of Professional Services
-
ESGold Corp. Secures $3.3 Million Financing to Advance into Near-Term Gold Production
-
Capstone Green Energy (CGEH) names Christopher Close to Board
-
Capstone Green Energy Appoints Christopher Close to Its Board of Directors
-
Bedrock's BR/USDT Pool Trading Volume Surpasses $13.2 Billion with Over 341,000 Traders in 5 Days
-
PracticeLink Announces Strategic Leadership Realignment to Advance Service to Physicians and Recruiters
-
Mitsubishi Tanabe Pharma America Marks Three Years Since Launch of RADICAVA ORS® (edaravone) in the U.S.
-
Affinity Interactive’s Daily Racing Form Partners with Horseshoe Indianapolis to Launch Groundbreaking AI Handicapping Technology for 2025 Racing Season
-
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions
-
Anchorage Digital Adopts Uniswap’s API Enabling Institutional Access to DeFi Liquidity
-
General Enterprise Ventures Strengthens Canada's Wildfire Defense in Partnership with Global Fire Rescue
-
Conduent to Showcase Innovative 3D Fare Gates and Other Transit Technologies at Transport Ticketing North America
-
Worksport Reports Consecutive Months of Record-Breaking Revenues, Gross Margin Improves by 25%
-
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
-
ValueSelling Associates Launches AI Avatar Sales Coach, “Val”
-
ReElement Technologies Corporation and Pensana PLC Join Forces to Advance One of Largest Global Rare Earth Oxide Supply Chain Partnerships
-
Telvantis Inc. Closes May 25 With $20.6M+ in Revenue; Confirms Full Year Plan in Excess of $200M in Revenues and Strong Commercial Momentum
-
John Wiley & Sons, Inc. (WLY) Appoints Craig Albright as CFO
-
Coalfire Sets the Bar for Responsible AI, Unveiling Industry's First ISO 42001 Certification and Comprehensive Model Testing Program
-
Anixa Biosciences (ANIX) Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
-
Wiley Appoints Craig Albright as Executive Vice President and Chief Financial Officer
-
FIFA, NBA, UFC and More Sports Events Go Live – Crypto Sportsbook BETY Offers Global Sports Betting Coverage 2025
-
Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM
-
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
-
Toshiba Automates Busywork, Frees Time
-
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
-
Telvantis Inc. Closes May 25 With $20.6M+ in Revenue; Confirms Full Year Plan in Excess of $200M in Revenues and Strong Commercial Momentum
-
Guardforce AI Strengthens Decade-Long Client Relationships by Securing Long-term Contract with Government Savings Bank
-
Quanterix (QTRX) Expands Reach with IVD and Large Reference Labs
-
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
-
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
-
Turnium Technology Group and Syntheia AI Forge Global Strategic Alliance to Accelerate AI Innovation and Market Reach
-
Quanterix Expands Reach with IVD and Large Reference Labs
-
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
-
SIROCCO BY LEBUA AWARDED TWO FORKS BY GAMBERO ROSSO
-
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
-
Merck (MRK) Announces Phase 3 HYPERION Study of WINREVAIR Met Primary Endpoint
-
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
-
BYDFi MoonX Launches Global KOL Recruitment to Accelerate the On-Chain Trading Ecosystems
-
Vanilla Finance Rebrands to Superp, A Meme-Fueled Perp DEX
-
Quantum International Corporation Launches New Website Showcasing Innovative Web3 and AI Solutions
-
New Research Portal Offers Access to Longitudinal FSHD Patient Data
-
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
-
Bitget Onboards on India's I4C’s Sahyog Portal to Support Local Law Enforcement
-
Bitget Onboards on India's I4C’s Sahyog Portal to Support Local Law Enforcement
-
Deepcoin Integrates TradingView Webhook for Automated Perpetual Trading Execution
-
Claranova: Signature of Agreement for the Sale of the PlanetArt Business
-
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
-
Loop Industries Announces $1.5 Million Engineering Services Agreement for Infinite Loop India Project
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Krispy Kreme, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DNUT
